882 related articles for article (PubMed ID: 24841269)
21. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
22. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
23. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
[TBL] [Abstract][Full Text] [Related]
24. Development of Small-Molecule MERS-CoV Inhibitors.
Liang R; Wang L; Zhang N; Deng X; Su M; Su Y; Hu L; He C; Ying T; Jiang S; Yu F
Viruses; 2018 Dec; 10(12):. PubMed ID: 30562987
[TBL] [Abstract][Full Text] [Related]
25. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
[TBL] [Abstract][Full Text] [Related]
26. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.
Cong Y; Hart BJ; Gross R; Zhou H; Frieman M; Bollinger L; Wada J; Hensley LE; Jahrling PB; Dyall J; Holbrook MR
PLoS One; 2018; 13(3):e0194868. PubMed ID: 29566060
[TBL] [Abstract][Full Text] [Related]
27. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
Persoons L; Vanderlinden E; Vangeel L; Wang X; Do NDT; Foo SC; Leyssen P; Neyts J; Jochmans D; Schols D; De Jonghe S
Antiviral Res; 2021 Sep; 193():105127. PubMed ID: 34217752
[TBL] [Abstract][Full Text] [Related]
28. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
29. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
30. Antiviral drugs specific for coronaviruses in preclinical development.
Adedeji AO; Sarafianos SG
Curr Opin Virol; 2014 Oct; 8():45-53. PubMed ID: 24997250
[TBL] [Abstract][Full Text] [Related]
31. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.
de Wilde AH; Raj VS; Oudshoorn D; Bestebroer TM; van Nieuwkoop S; Limpens RWAL; Posthuma CC; van der Meer Y; Bárcena M; Haagmans BL; Snijder EJ; van den Hoogen BG
J Gen Virol; 2013 Aug; 94(Pt 8):1749-1760. PubMed ID: 23620378
[TBL] [Abstract][Full Text] [Related]
32. Ca
Straus MR; Tang T; Lai AL; Flegel A; Bidon M; Freed JH; Daniel S; Whittaker GR
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295925
[TBL] [Abstract][Full Text] [Related]
33. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
34. Natural and Nature-Derived Products Targeting Human Coronaviruses.
Vougogiannopoulou K; Corona A; Tramontano E; Alexis MN; Skaltsounis AL
Molecules; 2021 Jan; 26(2):. PubMed ID: 33467029
[TBL] [Abstract][Full Text] [Related]
35. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
[TBL] [Abstract][Full Text] [Related]
36. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
37. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.
Lin MH; Moses DC; Hsieh CH; Cheng SC; Chen YH; Sun CY; Chou CY
Antiviral Res; 2018 Feb; 150():155-163. PubMed ID: 29289665
[TBL] [Abstract][Full Text] [Related]
38. Nucleoside analogues for the treatment of coronavirus infections.
Pruijssers AJ; Denison MR
Curr Opin Virol; 2019 Apr; 35():57-62. PubMed ID: 31125806
[TBL] [Abstract][Full Text] [Related]
39. High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery.
Ge F; Xiong S; Lin FS; Zhang ZP; Zhang XE
Antiviral Res; 2008 Nov; 80(2):107-13. PubMed ID: 18584889
[TBL] [Abstract][Full Text] [Related]
40. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.
Chan JF; Chan KH; Kao RY; To KK; Zheng BJ; Li CP; Li PT; Dai J; Mok FK; Chen H; Hayden FG; Yuen KY
J Infect; 2013 Dec; 67(6):606-16. PubMed ID: 24096239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
